Rad140 Capsules (15mg) 60 Count
- Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
- Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
- Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use
$119.00
$99.00